Closing the production gap in gene therapy – A scalable helper virus-free AAV production platform

Sponsor

With gene therapy projects moving towards more common diseases, such as Rheumatoid Arthritis, Parkinson´s disease or Alzheimer´s disease, there is a growing need for large-scale viral vector production, in particular for adeno-associated viral (AAV) vectors. However, current production systems rely on transient plasmid transfection or helper viruses and are thus hardly scalable. The webinar will address solutions to overcome this production gap in gene therapy.

Watch this On Demand Webinar with Dr Nicole Faust, CEO & CSO at CEVEC, Dr Clive Glover, Director of Strategy at Pall, Dr Andy Topping, Chief Scientific Officer at FUJIFILM Diosynth Biotechnologies and Dr Philip Wills, Chief Commercial Officer at Paragon Bioservices as you learn how CEVEC´s stable, helper virus-free AAV platform overcomes scalability issues by moving AAV production to stable producer cells.